Credit Suisse’s Verrica Pharmaceuticals VRCA Stock Holding History

Credit Suisse’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	4323
2022 Q2	$0	Buy	+1	New	+$50	﹤0.01%	4354

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Credit Suisse's VRCA Position: Q3 2022 in Review

Credit Suisse sold out of Verrica Pharmaceuticals (VRCA) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in VRCA in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 49 funds tracked by Wall St. Rank hold VRCA as of Q3 2022.

Credit Suisse reported no remaining Verrica Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 1 Verrica Pharmaceuticals share in Q3 2022.
Credit Suisse first reported a position in Verrica Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Credit Suisse's Verrica Pharmaceuticals position peaked at $0 in Q2 2022.
49 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.